GlassScriptPhysician profile
Caitlin Daughtry
NPI 1215571054
$7,352.83
in general payments reported to CMS, 2019-2025
28 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.17 · 2022: $1,211 · 2023: $1,619 · 2024: $2,210 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,000 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,000.06 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,737.65 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $870.51 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $821.27 | 2022-2025 | Caplyta |
| Lundbeck LLC | $537.21 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $497.36 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $416.28 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $295.37 | 2022-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $243.47 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $239.30 | 2022-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $230.42 | 2022-2025 | Wellbutrin, Aplenzin |
| Neos Therapeutics, LP | $204.12 | 2022-2025 | Adzenys Xr-Odt |
| Corium, LLC | $188.19 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $177.50 | 2023-2025 | Ingrezza |
| Tms Neurohealth Centers INC. | $113.45 | 2025 | Tms Neurohealth Centers INC. |
| Alkermes, INC. | $109.76 | 2023 | Lybalvi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $101.51 | 2022-2023 | Hetlioz |
| Teva Pharmaceuticals USA, INC. | $99.70 | 2023-2025 | Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $91.16 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $68.94 | 2024 | Loreev Xr |
| Intersect Ent, INC. | $48.39 | 2021 | |
| Biogen, INC. | $46.68 | 2025 | Zurzuvae |
| Tris Pharma INC | $46.53 | 2023 | Dyanavel Xr |
| Stryker Corporation | $44.78 | 2021 | |
| Optinose US, INC. | $38.75 | 2022 | |
| Sunovion Pharmaceuticals INC. | $29.49 | 2022 | |
| Noven Therapeutics, LLC | $18.44 | 2023 | Secuado |
| E.R. Squibb & Sons, L.L.C. | $18.32 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Daughtry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.